Related Experiment Video
Updated: Jun 28, 2026

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
Neurochemical dementia diagnostics: assays in CSF and blood
Piotr Lewczuk1, Joachim Hornegger, Rüdiger Zimmermann
1Department of Psychiatry and Psychotherapy, Universitätsklinikum Erlangen, Schwabachanlage 6, Erlangen, Germany.
Abstract:
In this review, current neurochemical dementia diagnostics (NDD) procedures are presented with a focus on biomarkers in the cerebrospinal fluid (CSF) and blood: amyloid beta peptides, tau protein, and its phosphorylated form (pTau). CSF analysis is an increasingly important tool for early and differential diagnosis of dementia syndromes. Although lumbar puncture is a mildly invasive procedure with a low incidence of complications, establishing blood assays capable of reliably measuring NDD biomarkers is an aim of several studies worldwide.
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Dementia l: Introduction
Dementia
The progression of dementia is generally gradual.

